What is HC Wainwright's Estimate for NRIX FY2027 Earnings?

Key Points

• HC Wainwright estimates Nurix Therapeutics will report a FY2027 loss of $2.42 per share and maintains a “Buy” rating with a $36 price target.
• Nurix’s latest quarterly results significantly exceeded expectations, with EPS of $4.73 versus the $0.60 consensus loss estimate and revenue of $673.06 million versus $24.35 million expected.
• Analyst sentiment remains broadly positive: 13 analysts rate the stock “Buy,” with a consensus target price of $34.79, while shares recently traded at $24.42.

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) - HC Wainwright issued their FY2027 earnings estimates for Nurix Therapeutics in a research note issued to investors on Friday, October 16th. HC Wainwright analyst R. Burns anticipates that the company will earn ($2.42) per share for the year. HC Wainwright has a "Buy" rating and a $36.00 price target on the stock. The consensus estimate for Nurix Therapeutics' current full-year earnings is $1.15 per share.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its quarterly earnings data on Monday, October 12th. The company reported $4.73 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.60) by $5.33. Nurix Therapeutics had a net margin of 42.01% and a return on equity of 49.34%. The firm had revenue of $673.06 million for the quarter, compared to analysts' expectations of $24.35 million.

Other research analysts also recently issued research reports about the company. UBS Group increased their price target on Nurix Therapeutics from $23.00 to $31.00 and gave the company a "buy" rating in a research note on Wednesday, July 22nd. Robert W. Baird lifted their price objective on Nurix Therapeutics from $33.00 to $36.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 13th. Needham & Company LLC reaffirmed a "buy" rating and set a $34.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday, October 13th. Truist Financial dropped their price objective on Nurix Therapeutics from $34.00 to $33.00 and set a "buy" rating for the company in a report on Tuesday, October 13th. Finally, Morgan Stanley upped their price objective on Nurix Therapeutics from $36.00 to $38.00 and gave the company an "overweight" rating in a report on Tuesday, July 28th. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $34.79.

Nurix Therapeutics Stock Performance

Shares of Nurix Therapeutics stock opened at $24.42 on Monday. The firm has a fifty day moving average of $25.11 and a two-hundred day moving average of $21.20. The stock has a market capitalization of $2.67 billion, a price-to-earnings ratio of 10.57 and a beta of 1.82. Nurix Therapeutics has a 52 week low of $9.71 and a 52 week high of $28.23.

Insider Activity at Nurix Therapeutics

In other news, CFO Hans van Houte sold 4,761 shares of Nurix Therapeutics stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $24.36, for a total transaction of $115,977.96. Following the transaction, the chief financial officer directly owned 40,166 shares of the company's stock, valued at $978,443.76. This trade represents a 10.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 4,356 shares of Nurix Therapeutics stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $25.00, for a total transaction of $108,900.00. Following the transaction, the insider directly owned 117,227 shares in the company, valued at approximately $2,930,675. This represents a 3.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 45,407 shares of company stock worth $1,083,206. 6.70% of the stock is currently owned by company insiders.

Institutional Trading of Nurix Therapeutics

Large investors have recently made changes to their positions in the company. Trails Edge Capital Partners LP acquired a new position in Nurix Therapeutics in the second quarter valued at about $38,166,318. Bank of New York Mellon Corp bought a new stake in shares of Nurix Therapeutics in the second quarter worth about $6,614,000. Man Group plc bought a new stake in shares of Nurix Therapeutics in the second quarter worth about $2,076,000. Bank of America Corp DE bought a new stake in shares of Nurix Therapeutics in the second quarter worth about $20,429,000. Finally, Perceptive Advisors LLC raised its position in shares of Nurix Therapeutics by 4.4% during the first quarter. Perceptive Advisors LLC now owns 3,710,877 shares of the company's stock worth $57,519,000 after purchasing an additional 155,000 shares during the period.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a biopharmaceutical company focused on developing medicines that regulate the levels and activity of disease-causing proteins. Headquartered in San Francisco, California, the company uses its DELigase platform to discover therapies based on targeted protein degradation and immune-system modulation.

Nurix's pipeline includes oral targeted protein degraders designed to eliminate specific proteins involved in cancer and immune-cell function. Its lead programs have included NX-5948, a Bruton's tyrosine kinase degrader being evaluated for certain B-cell malignancies, and NX-2127, an investigational degrader designed to target BTK and other proteins relevant to cancer biology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.